f-Star, Merck Serono Sign $708 Million Deal for Antibody-Derived Therapeutics
Antibody engineering firm F-Star could earn up to €492 million as part of a research, license, and commercialization deal with Merck Serono centered on the discovery of antibody-derived therapeutics against inflammatory disease targets. Under terms of the deal, the partners will work together to exploit F-Star’s Modular Antibody Technology for the discovery of monospecific Fc-based targeted biologics (Fcabs) and bispecific IgG-based targeted biologics (mAb² ™) against up to three Merck Serono targets. Merck Serono will have exclusive worldwide development and commercialization rights to resulting products. As well as an initial technology access fee and research-based funding, F-Star will be eligible for license fees, development, regulatory and commercialization milestones, and tiered royalties on product sales.